Trial Information

Summary: Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

A Phase IIIb, Open-Label, Follow-on Trial to C87085 Designed to Assess the Long-Term Safety of Certolizumab Pegol, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085

The primary objective of the study is to assess the safety of long term therapy with certolizumab pegol in those subjects participating in sudy C87085.

Inclusion Criteria:

• Subjects participated in study C87085

Exclusion Criteria:

• General exclusion criteria as common for open-label extension studies

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:45:59 AM